Article: 0266

Topic: EPO01 - e-Poster Oral 01: Schizophrenia 1

Tobacco Use and Clinical Symptoms in a Sample of Outpatients Diagnosed with Schizophrenia

P.A. Sáiz Martinez¹, S. Fernández-Artamendi¹, S. Al-Halabí¹, E. Díaz-Mesa¹, L. García-Álvarez¹, E.

Martínez², L. Nogueiras², M. Pouso³, R. Ramos³, T. Rodríguez⁴, G. Díaz-Flórez², M. Arrojo⁵, P. García-Portilla¹, J. Bobes¹

¹Área de Psiquiatría - Universidad de Oviedo, Centro de Investigación Biomédica En Red de Salud Mental,

Oviedo, Spain; ²Hospital Santa María Nai - CHOU, Unidad de Conductas Adictivas, Santiago de

Compostela, Spain; ³Departamento de Psiquiatría, Hospital Psiquiátrico de Conxo, Santiago de

Compostela, Spain; ⁴CSM La Ería, Servicios de Salud del Principado de Asturias, Oviedo, Spain; ⁵Servicio

de Psiguiatría, EOXI Santiago. IDIS. Servicio Gallego de Salud, Santiago de Compostela, Spain

Introduction: The self-medication hypothesis suggests that patients diagnosed with schizophrenia might smoke as an attempt to self-medicate their symptoms. As a consequence, smoking cessation could worsen their clinical status.

Objectives: To assess the clinical changes associated with tobacco cessation in a sample of smoking outpatients with schizophrenia.

Methods. Sample: 63 smoking outpatients with DSM-IV Schizophrenia from three Mental Health Centers located in Northern Spain [77.0% males; mean age (SD) = 43.90 (8.72); average daily cigarette use (SD) = 27.99 (12.55)]. Instruments: (1) Clinical symptoms: Positive and Negative Symptoms Scale (PANSS), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI). (2) Pattern of tobacco use: n° cigarettes/day; Expired carbon monoxide (CO ppm). Design: A quasi-experimental design with two groups was implemented: control group (GC - 18 patients not willing to stop smoking), and treatment group [TG - 45 patients in smoking cessation supported by nicotine patches or vareniclina (12 weeks)]. Patients were evaluated at baseline and at week 11 (end of program). Paired sample t-test was used to detect changes in clinical symptoms from baseline to follow-up.

Results: 23.1% stopped smoking (from TG). No significant differences were found between baseline and follow-up scores (p>.05) among smokers and abstinent in PANSS subscales, HDRS and CGI.

Conclusions: Tobacco cessation did not have a significant effect on the clinical symptoms of this group of patients. Further studies should analyze the stability of these outcomes at longer follow-ups to confirm our results.